Based on the analysis of Sanofi ADR's profitability, liquidity, and operating efficiency, Sanofi ADR is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in April. At this time, Sanofi ADR's Other Current Liabilities is fairly stable compared to the past year. Common Stock Shares Outstanding is likely to rise to about 1.6 B in 2025, whereas Total Assets are likely to drop slightly above 90.9 B in 2025. Key indicators impacting Sanofi ADR's financial strength include:
The essential information of the day-to-day investment outlook for Sanofi ADR includes many different criteria found on its balance sheet. An individual investor should monitor Sanofi ADR's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Sanofi ADR.
Please note, the imprecision that can be found in Sanofi ADR's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sanofi ADR. Check Sanofi ADR's Beneish M Score to see the likelihood of Sanofi ADR's management manipulating its earnings.
Sanofi ADR Stock Summary
Sanofi ADR competes with AstraZeneca PLC, Roche Holding, GlaxoSmithKline PLC, Merck, and Novartis. Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 95442 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Sanofi ADR. It measures of how well Sanofi is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Sanofi ADR brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Sanofi had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Sanofi ADR has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Sanofi ADR's current stock value. Our valuation model uses many indicators to compare Sanofi ADR value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sanofi ADR competition to find correlations between indicators driving Sanofi ADR's intrinsic value. More Info.
Sanofi ADR is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sanofi ADR is roughly 1.71 . At this time, Sanofi ADR's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sanofi ADR's earnings, one of the primary drivers of an investment's value.
Sanofi ADR's Earnings Breakdown by Geography
Sanofi ADR Systematic Risk
Sanofi ADR's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sanofi ADR volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Sanofi ADR correlated with the market. If Beta is less than 0 Sanofi ADR generally moves in the opposite direction as compared to the market. If Sanofi ADR Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sanofi ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sanofi ADR is generally in the same direction as the market. If Beta > 1 Sanofi ADR moves generally in the same direction as, but more than the movement of the benchmark.
Sanofi ADR Thematic Clasifications
Sanofi ADR is part of several thematic ideas from Giant Impact to Dividend Beast. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Sanofi ADR Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sanofi ADR's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Sanofi ADR growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Sanofi ADR help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sanofi ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sanofi ADR based on widely used predictive technical indicators. In general, we focus on analyzing Sanofi Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sanofi ADR's daily price indicators and compare them against related drivers.
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.